Genetics of uveal melanoma and cutaneous melanoma: Two of a kind?

Dermatology Research and Practice

Volumn 2010, Issue 1, 2010, Pages

  Van Den Bosch, Thomas ^a,b   Kilic, Emine ^b   Paridaens, Dion ^a   De Klein, Annelies ^b  

^a ROTTERDAM EYE HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79954586180     PISSN: None     EISSN: 16876113     Source Type: Journal    
DOI: 10.1155/2010/360136     Document Type: Review

References (134)

1. Garbe C., Blum A., Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacology and Applied Skin Physiology 2001 14 5 280 290 10.1159/000056358 2-s2.0-0035742712 (Pubitemid 34701635)
2. Giblin A.-V., Thomas J. M., Incidence, mortality and survival in cutaneous melanoma. Journal of Plastic, Reconstructive and Aesthetic Surgery 2007 60 1 32 40 10.1016/j.bjps.2006.05.008 2-s2.0-33751114201 (Pubitemid 44763123)
3. Nambiar S., Mirmohammadsadegh A., Hengge U. R., Cutaneous melanoma: fishing with chips. Current Molecular Medicine 2008 8 3 235 243 10.2174/156652408784221333 2-s2.0-45549106048 (Pubitemid 351982541)
4. Singh A. D., Bergman L., Seregard S., Uveal melanoma: epidemiologic aspects. Ophthalmology Clinics of North America 2005 18 1 75 84 10.1016/j.ohc.2004.07.002 2-s2.0-14844307061 (Pubitemid 40348812)
5. Diener-West M., Hawkins B. S., Markowitz J. A., Schachat A. P., A review of mortality from choroidal melanoma: II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Archives of Ophthalmology 1992 110 2 245 250 2-s2.0-0026595855
6. Harbour J. W., Molecular prognostic testing and individualized patient care in uveal melanoma. American Journal of Ophthalmology 2009 148 6 823 829 10.1016/j.ajo.2009.07.004 2-s2.0-70449685754
7. Schmidt-Pokrzywniak A., Jöckel K.-H., Bornfeld N., Sauerwein W., Stang A., Positive interaction between light iris color and ultraviolet radiation in relation to the risk of uveal melanoma: a case-control study. Ophthalmology 2009 116 2 340 348 10.1016/j.ophtha.2008.09.040 2-s2.0-58849120434
8. Shields J. A., Shields S. C., Intraocular Tumors: An Atlas and Textbook 2007 2nd Philadelphia, Pa, USA Lippincott Williams & Wilkins
9. Meyle K. D., Guldberg P., Genetic risk factors for melanoma. Human Genetics 2009 126 4 499 510 10.1007/s00439-009-0715-9 2-s2.0-70350152582
10. Singh A. D., De Potter P., Fijal B. A., Shields C. L., Shields J. A., Elston R. C., Lifetime prevalence of uveal melanoma in white patients with oculo(dermal) melanocytosis. Ophthalmology 1998 105 1 195 198 10.1016/S0161-6420(98)92205-9 2-s2.0-0031895268 (Pubitemid 28070622)
11. Moan J., Porojnicu A. C., Dahlback A., Ultraviolet radiation and malignant melanoma. Advances in Experimental Medicine and Biology 2008 624 104 116 10.1007/978-0-387-77574-6-9 2-s2.0-42949125395
12. Saida T., Lessons learned from studies of the development of early melanoma. International Journal of Clinical Oncology 2005 10 6 371 374 10.1007/s10147-005-0539-0 2-s2.0-29244492256 (Pubitemid 41821519)
13. Shields C. L., The hunt for the secrets of uveal melanoma. Clinical and Experimental Ophthalmology 2008 36 3 277 280 10.1111/j.1442-9071.2008.01717.x 2-s2.0-42449102183 (Pubitemid 351560278)
14. Miller A. J., Mihm M. C. Jr., Melanoma. The New England Journal of Medicine 2006 355 1 51 65 2-s2.0-0033081066 10.1056/NEJMra052166
15. Bedikian A. Y., Legha S. S., Mavligit G., Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995 76 9 1665 1670 10.1002/1097-0142(19951101) 76:9<1665::AID-CNCR2820760925>3.0.CO;2-J 2-s2.0-0028853939
16. Kujala E., Mäkitie T., Kivelä T., Very long-term prognosis of patients with malignant uveal melanoma. Investigative Ophthalmology and Visual Science 2003 44 11 4651 4659 10.1167/iovs.03-0538 2-s2.0-0142200859 (Pubitemid 37315273)
17. Bedikian A. Y., Millward M., Pehamberger H., Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. Journal of Clinical Oncology 2006 24 29 4738 4745 10.1200/JCO.2006.06.0483 2-s2.0-33750600634 (Pubitemid 46630937)
18. Tsao H., Atkins M. B., Sober A. J., Management of cutaneous melanoma. The New England Journal of Medicine 2004 351 10 998 1012 10.1056/NEJMra041245 2-s2.0-4344656396 (Pubitemid 39166263)
19. Vahrmeijer A. L., van de Velde C. J. H., Hartgrink H. H., Tollenaar R. A. E. M., Treatment of melanoma metastases confined to the liver and future perspectives. Digestive Surgery 2009 25 6 467 472 10.1159/000184738 2-s2.0-60149087726
20. Bedikian A. Y., Metastatic uveal melanoma therapy: current options. International Ophthalmology Clinics 2006 46 1 151 166 10.1097/01.iio.0000195852. 08453.de 2-s2.0-33644873740 (Pubitemid 44124237)
21. Leiter U., Meier F., Schittek B., Garbe C., The natural course of cutaneous melanoma. Journal of Surgical Oncology 2004 86 4 172 178 10.1002/jso.20079 2-s2.0-3042777370 (Pubitemid 38880283)
22. Gragoudas E. S., Egan K. M., Seddon J. M., Survival of patients with metastases from uveal melanoma. Ophthalmology 1991 98 3 383 390 2-s2.0-0025962917
23. Onken M. D., Worley L. A., Harbour J. W., A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis. Clinical Cancer Research 2008 14 12 3737 3745 10.1158/1078-0432.CCR- 07-5144 2-s2.0-52449123778
24. Gragoudas E. S., Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld lecture. Investigative Ophthalmology and Visual Science 2006 47 11 4666 4673 10.1167/iovs.06-0659 2-s2.0-34247095590 (Pubitemid 46586360)
25. Willson J. K.V., Albert D. M., Diener-West M., Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (coms) coms report no. 15. Archives of Ophthalmology 2001 119 5 670 676 2-s2.0-13144306078 (Pubitemid 32417373)
26. Diener-West M., Reynolds S. M., Agugliaro D. J., Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. Journal of Clinical Oncology 2004 22 12 2438 2444 10.1200/JCO.2004.08.194 2-s2.0-2942754161 (Pubitemid 41115402)
27. Landreville S., Agapova O. A., Hartbour J. W., Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncology 2008 4 5 629 636 10.2217/14796694.4.5.629 2-s2.0-55249105711
28. Eskelin S., Pyrhönen S., Summanen P., Hahka-Kemppinen M., Kivelä T., Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology 2000 107 8 1443 1449 10.1016/S0161-6420(00)00182-2 2-s2.0-0033769530
29. Shields C. L., Shields J. A., Kiratli H., De Potter P., Cater J. R., McLean I. W., Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology 1995 102 9 1351 1361 2-s2.0-0029100258
30. Shields C. L., Cater J., Shields J. A., Singh A. D., Santos M. C. M., Carvalho C., Combination of clinical factors predictive of growth of small choroidal melanocytic tumors. Archives of Ophthalmology 2000 118 3 360 364 2-s2.0-0034103212 (Pubitemid 30152376)
31. Diener-West M., Reynolds S. M., Agugliaro D. J., Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative Ocular Melanoma Study Group Report No. 26. Archives of Ophthalmology 2005 123 12 1639 1643 10.1001/archopht.123.12.1639 2-s2.0-28944437419 (Pubitemid 41785095)
32. Damato B., Legacy of the collaborative ocular melanoma study. Archives of Ophthalmology 2007 125 7 966 968 10.1001/archopht.125.7.966 2-s2.0-34447508449 (Pubitemid 47076439)
33. Onken M. D., Worley L. A., Ehlers J. P., Harbour J. W., Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Research 2004 64 20 7205 7209 10.1158/0008-5472.CAN-04- 1750 2-s2.0-5644251671 (Pubitemid 39372052)
34. Balch C. M., Buzaid A. C., Soong S.-J., New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Seminars in Surgical Oncology 2003 21 1 43 52 10.1002/ssu.10020 2-s2.0-10744230605 (Pubitemid 37127473)
35. van Dekken H., Pizzolo J. G., Reuter V. E., Melamed M. R., Cytogenetic analysis of human solid tumors by in situ hybridization with a set of 12 chromosome-specific DNA probes. Cytogenetics and Cell Genetics 1990 54 3-4 103 107 2-s2.0-0025689326
36. Trask B. J., Fluorescence in situ hybridization: applications in cytogenetics and gene mapping. Trends in Genetics 1991 7 5 149 154 2-s2.0-0025729359 (Pubitemid 121001914)
37. Damato B., Dopierala J., Klaasen A., van Dijk M., Sibbring J., Coupland S. E., Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Investigative Ophthalmology & Visual Science 2009 50 7 3048 3055 2-s2.0-67649961694
38. Horsman D. E., Sroka H., Rootman J., White V. A., Monosomy 3 and isochromosome 8q in a uveal melanoma. Cancer Genetics and Cytogenetics 1990 45 2 249 253 10.1016/0165-4608(90)90090-W 2-s2.0-0025342575 (Pubitemid 20129149)
39. Prescher G., Bornfeld N., Becher R., Nonrandom chromosomal abnormalities in primary uveal melanoma. Journal of the National Cancer Institute 1990 82 22 1765 1769 2-s2.0-0025611594
40. Sisley K., Rennie I. G., Cottam D. W., Potter A. M., Potter C. W., Rees R. C., Cytogenetic findings in six posterior uveal melanomas: involvement of chromosomes 3, 6, and 8. Genes Chromosomes and Cancer 1990 2 3 205 209 2-s2.0-0025039289 (Pubitemid 20369595)
41. Scholes A. G. M., Damato B. E., Nunn J., Hiscott P., Grierson I., Field J. K., Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Investigative Ophthalmology and Visual Science 2003 44 3 1008 1011 10.1167/iovs.02-0159 2-s2.0-0037336215 (Pubitemid 36297813)
42. Höglund M., Gisselsson D., Hansen G. B., Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution. International Journal of Cancer 2004 108 1 57 65 10.1002/ijc.11558 2-s2.0-0345256382 (Pubitemid 37444444)
43. White V. A., Chambers J. D., Courtright P. D., Chang W. Y., Horsman D. E., Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 1998 83 2 354 359 10.1002/(SICI)1097-0142(19980715)83: 2<354::AID-CNCR20>3.0.CO;2-R 2-s2.0-0032528210 (Pubitemid 28317816)
44. Prescher G., Bornfeld N., Hirche H., Horsthemke B., Jöckel K.-H., Becher R., Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996 347 9010 1222 1225 10.1016/S0140-6736(96)90736-9 2-s2.0-0029874486 (Pubitemid 26131850)
45. Sisley K., Rennie I. G., Parsons M. A., Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes and Cancer 1997 19 1 22 28 10.1002/(SICI)1098-2264(199705)19:1<22::AID- GCC4>3.0.CO;2-2 2-s2.0-0030982005 (Pubitemid 27193716)
46. Sisley K., Parsons M. A., Garnham J., Association of specific chromosome alterations with tumour phenotype in posterior uveal melanoma. British Journal of Cancer 2000 82 2 330 338 2-s2.0-0033954096 (Pubitemid 30045378)
47. Horsthemke B., Prescher G., Bornfeld N., Becher R., Loss of chromosome 3 alleles and multiplication of chromosome 8 alleles in uveal melanoma. Genes Chromosomes and Cancer 1992 4 3 217 221 10.1002/gcc.2870040305 2-s2.0-0026569064
48. Aalto Y., Eriksson L., Seregard S., Larsson O., Knuutila S., Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Investigative Ophthalmology and Visual Science 2001 42 2 313 317 2-s2.0-0035146240 (Pubitemid 32121456)
49. Prescher G., Bornfeld N., Friedrichs W., Seeber S., Becher R., Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation. Cancer Genetics and Cytogenetics 1995 80 1 40 46 10.1016/0165-4608(94)00165-8 2-s2.0-0028915558
50. Onken M. D., Worley L. A., Person E., Char D. H., Bowcock A. M., Harbour J. W., Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clinical Cancer Research 2007 13 10 2923 2927 10.1158/1078-0432.CCR- 06-2383 2-s2.0-34249781123 (Pubitemid 46849567)
51. Parrella P., Fazio V. M., Gallo A. P., Sidransky D., Merbs S. L., Fine mapping of chromosome 3 in uveal melanoma: identification of a minimal region of deletion on chromosomal arm 3p25.1-p25.2. Cancer Research 2003 63 23 8507 8510 2-s2.0-0345734263 (Pubitemid 37549508)
52. Tschentscher F., Hüsing J., Hölter T., Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Research 2003 63 10 2578 2584 2-s2.0-0026575353 (Pubitemid 36608917)
53. van Gils W., Lodder E. M., Mensink H. W., Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis. Investigative Ophthalmology and Visual Science 2008 49 10 4254 4262 10.1167/iovs.08-2033 2-s2.0-53449099872
54. Onken M. D., Ehlers J. P., Worley L. A., Makita J., Yokota Y., Harbour J. W., Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Research 2006 66 9 4602 4609 10.1158/0008-5472.CAN-05-4196 2-s2.0-33646405726
55. Worley L. A., Onken M. D., Person E., Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clinical Cancer Research 2007 13 5 1466 1471 10.1158/1078-0432.CCR-06-2401 2-s2.0-33947409634 (Pubitemid 46450436)
56. Petrausch U., Martus P., Tönnies H., Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye 2008 22 8 997 1007 10.1038/sj.eye. 6702779 2-s2.0-43649103257
57. Horsman D. E., White V. A., Cytogenetic analysis of uveal melanoma: consistent occurrence of monosomy 3 and trisomy 8q. Cancer 1993 71 3 811 819 10.1002/1097-0142(19930201)71:3<811::AID-CNCR2820710325>3.0.CO;2-F 2-s2.0-0027506157 (Pubitemid 23051386)
58. Kilic E., van Gils W., Lodder E., Clinical and cytogenetic analyses in uveal melanoma. Investigative Ophthalmology and Visual Science 2006 47 9 3703 3707 10.1167/iovs.06-0101 2-s2.0-33749149897 (Pubitemid 46044279)
59. Sisley K., Tattersall N., Dyson M., Smith K., Mudhar H. S., Rennie I. G., Multiplex fluorescence in situ hybridization identifies novel rearrangements of chromosomes 6, 15, and 18 in primary uveal melanoma. Experimental Eye Research 2006 83 3 554 559 10.1016/j.exer.2006.02.007 2-s2.0-33746869266 (Pubitemid 44183803)
60. Hughes S., Damato B. E., Giddings I., Hiscott P. S., Humphreys J., Houlston R. S., Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3. British Journal of Cancer 2005 93 10 1191 1196 10.1038/sj.bjc.6602834 2-s2.0-27944511525 (Pubitemid 41670705)
61. Parrella P., Caballero O. L., Sidransky D., Merbs S. L., Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization. Investigative Ophthalmology and Visual Science 2001 42 8 1679 1684 2-s2.0-0034942895 (Pubitemid 32652337)
62. Ehlers J. P., Harbour J. W., NBS1 expression as a prognostic marker in uveal melanoma. Clinical Cancer Research 2005 11 5 1849 1853 10.1158/1078-0432.CCR-04-2054 2-s2.0-16344362449 (Pubitemid 40471849)
63. Ehlers J. P., Worley L., Onken M. D., Harbour J. W., DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma. Clinical Cancer Research 2005 11 10 3609 3613 10.1158/1078-0432.CCR-04-1941 2-s2.0-18844368501 (Pubitemid 40685575)
64. Amati B., Alevizopoulos K., Vlach J., Myc and the cell cycle. Frontiers in Bioscience 1998 3 D250 D268
65. Kilic E., Naus N. C., van Gils W., Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Investigative Ophthalmology and Visual Science 2005 46 7 2253 2257 10.1167/iovs.04-1460 2-s2.0-23244451088 (Pubitemid 43119466)
66. van Gils W., Mensink H. W., Kilic E., Expression of APITD1 is not related to copy number changes of chromosomal region 1p36 or the prognosis of uveal melanoma. Investigative Ophthalmology and Visual Science 2007 48 11 4919 4923 10.1167/iovs.07-0061 2-s2.0-38449120296 (Pubitemid 351260898)
67. Häusler T., Stang A., Anastassiou G., Loss of heterozygosity of 1p in uveal melanomas with monosomy 3. International Journal of Cancer 2005 116 6 909 913 2-s2.0-2942752374 10.1002/ijc.21086 (Pubitemid 41209197)
68. Parrella P., Sidransky D., Merbs S. L., Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway. Cancer Research 1999 59 13 3032 3037 2-s2.0-0033168843 (Pubitemid 29315995)
69. Ehlers J. P., Harbour J. W., Molecular pathobiology of uveal melanoma. International Ophthalmology Clinics 2006 46 1 167 180 10.1097/01.iio.0000195855. 31324.db 2-s2.0-33644876972 (Pubitemid 44124238)
70. Ghazvini S., Char D. H., Kroll S., Waldman F. M., Pinkel D., Comparative genomic hybridization analysis of archival formalin-fixed paraffin-embedded uveal melanomas. Cancer Genetics and Cytogenetics 1996 90 2 95 101 10.1016/S0165-4608(96)00076-3 2-s2.0-0030248391 (Pubitemid 26314890)
71. Papp T., Pemsel H., Zimmermann R., Bastrop R., Weiss D. G., Schiffmann D., Mutational analysis of the N-ras, p53, p16(INK4a), CDK4, and MC1R genes in human congenital melanocytic naevi. Journal of Medical Genetics 1999 36 8 610 614 2-s2.0-0032767677 (Pubitemid 29368901)
72. Demunter A., Stas M., Degreef H., De Wolf-Peeters C., van den Oord J. J., Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. Journal of Investigative Dermatology 2001 117 6 1483 1489 2-s2.0-0035670803 10.1046/j.0022-202x.2001.01601.x (Pubitemid 34032777)
73. Stahl J. M., Sharma A., Cheung M., Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Research 2004 64 19 7002 7010 10.1158/0008-5472.CAN-04-1399 2-s2.0-4944249733 (Pubitemid 39331010)
74. Davies H., Bignell G. R., Cox C., Mutations of the BRAF gene in human cancer. Nature 2002 417 6892 949 954 10.1038/nature00766 2-s2.0-18444374405 (Pubitemid 34716871)
75. Pollock P. M., Meltzer P. S., A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2002 2 1 5 7 10.1016/S1535-6108(02) 00089-2 2-s2.0-0036654443 (Pubitemid 41043982)
76. Greene V. R., Johnson M. M., Grimm E. A., Ellerhorst J. A., Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. Journal of Investigative Dermatology 2009 129 6 1483 1488 10.1038/jid.2008.374 2-s2.0-67349167716
77. Meyer P., Stapelmann H., Frank B., Molecular genetic analysis of NBS1 in German melanoma patients. Melanoma Research 2007 17 2 109 116 10.1097/CMR.0b013e3280dec638 2-s2.0-34247639965 (Pubitemid 46673904)
78. Kraehn G. M., Utikal J., Udart M., Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. British Journal of Cancer 2001 84 1 72 79 10.1054/bjoc.2000.1535 2-s2.0-0035134989 (Pubitemid 32102507)
79. Treszl A., Ádány R., Rákosy Z., Extra copies of c-myc are more pronounced in nodular melanomas than in superficial spreading melanomas as revealed by fluorescence in situ hybridisation. Cytometry Part B 2004 60 1 37 46 2-s2.0-3042789990 (Pubitemid 38885704)
80. Stark M., Hayward N., Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Research 2007 67 6 2632 2642 10.1158/0008-5472.CAN-06-4152 2-s2.0-34047258036 (Pubitemid 46548950)
81. van Raamsdonk C. D., Bezrookove V., Green G., Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009 457 7229 599 602 10.1038/nature07586 2-s2.0-59049107421
82. Curtin J. A., Fridlyand J., Kageshita T., Distinct sets of genetic alterations in melanoma. The New England Journal of Medicine 2005 353 20 2135 2147 10.1056/NEJMoa050092 2-s2.0-27844567142 (Pubitemid 41653105)
83. Jönsson G., Dahl C., Staaf J., Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene 2007 26 32 4738 4748 10.1038/sj.onc.1210252 2-s2.0-34447515273 (Pubitemid 47067402)
84. Sauter E. R., Yeo U.-C., Von Stemm A., Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Research 2002 62 11 3200 3206 2-s2.0-0036605974 (Pubitemid 34602414)
85. Ibrahim N., Haluska F. G., Molecular pathogenesis of cutaneous melanocytic neoplasms. Annual Review of Pathology 2009 4 551 579 10.1146/annurev.pathol.3.121806.151541 2-s2.0-66149090765
86. Jansen B., Schlagbauer-Wadl H., Brown B. D., BCL-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Medicine 1998 4 2 232 234 10.1038/nm0298-232 2-s2.0-0031907428 (Pubitemid 28137379)
87. Pons M., Mancheño-Corvo P., Martín-Duque P., Quintanilla M., Molecular biology of malignant melanoma. Advances in Experimental Medicine and Biology 2008 624 252 264 10.1007/978-0-387-77574-6-20 2-s2.0-42949129550
88. Quelle D. E., Zindy F., Ashmun R. A., Sherr C. J., Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995 83 6 993 1000 10.1016/0092-8674(95) 90214-7 2-s2.0-0029587551 (Pubitemid 26006540)
89. Kamb A., Gruis N. A., Weaver-Feldhaus J., A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994 264 5157 436 2-s2.0-0028121279 (Pubitemid 24178909)
90. Sharpless N. E., Chin L., Lynda-Chin@dfci.harvard.edu The INK4a / ARF locus and melanoma. Oncogene 2003 22 20 3092 3098 2-s2.0-0029664339 10.1038/sj.onc.1206461 (Pubitemid 36713761)
91. Goldstein A. M., Chan M., Harland M., Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. Journal of Medical Genetics 2007 44 2 99 106 10.1136/jmg.2006.043802 2-s2.0-33847282821
92. Wu H., Goel V., Haluska F. G., haluska.frank@mgh.harvard.edu PTEN signaling pathways in melanoma. Oncogene 2003 22 20 3113 3122 2-s2.0-0038456399 10.1038/sj.onc.1206451 (Pubitemid 36713763)
93. Tsao H., Zhang X., Benoit E., Haluska F. G., Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998 16 26 3397 3402 2-s2.0-0032474749 (Pubitemid 28349682)
94. Tsao H., Zhang X., Fowlkes K., Haluska F. G., Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Research 2000 60 7 1800 1804 2-s2.0-0034085811 (Pubitemid 30207633)
95. Mooy C. M., van der Helm M. J., van der Kwast T. H., De Jong P. T. V. M., Ruiter D. J., Zwarthoff E. C., No N-ras mutations in human uveal melanoma: the role of ultraviolet light revisited. British Journal of Cancer 1991 64 2 411 413 2-s2.0-0025769907
96. Kiliç E., Brüggenwirth H. T., Verbiest M. M. P. J., The RAS-BRAF kinase pathway is not involved in uveal melanoma. Melanoma Research 2004 14 3 203 205 10.1097/01.cmr.0000130006.46885.a0 2-s2.0-3042718312 (Pubitemid 38879582)
97. Saldanha G., Purnell D., Fletcher A., Potter L., Gillies A., Pringle J. H., High BRAF mutation frequency does not characterize all melanocytic tumor types. International Journal of Cancer 2004 111 5 705 710 10.1002/ijc.20325 2-s2.0-4043163497 (Pubitemid 39062892)
98. Janssen C. S., Sibbett R., Henriquez F. L., McKay I. C., Kemp E. G., Roberts F., The T1799A point mutation is present in posterior uveal melanoma. British Journal of Cancer 2008 99 10 1673 1677 10.1038/sj.bjc.6604731 2-s2.0-55949118418
99. Cohen Y., Goldenberg-Cohen N., Parrella P., Lack of BRAF mutation in primary uveal melanoma. Investigative Ophthalmology and Visual Science 2003 44 7 2876 2878 10.1167/iovs.02-1329 2-s2.0-0037562846 (Pubitemid 36759747)
100. Henriquez F., Janssen C., Kemp E. G., Roberts F., The T1799A BRAF mutation is present in iris melanoma. Investigative Ophthalmology and Visual Science 2007 48 11 4897 4900 10.1167/iovs.07-0440 2-s2.0-38449123183
101. Spendlove H. E., Damato B. E., Humphreys J., Barker K. T., Hiscott P. S., Houlston R. S., BRAF mutations are detectable in conjunctival but not uveal melanomas. Melanoma Research 2004 14 6 449 452 10.1097/00008390-200412000-00003 2-s2.0-13544260790 (Pubitemid 40221134)
102. Falck J., Petrini J. H. J., Williams B. R., Lukas J., Bartek J., The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nature Genetics 2002 30 3 290 294 10.1038/ng845 2-s2.0-0036510055
103. Parrella P., Caballero O. L., Sidransky D., Merbs S. L., Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization. Investigative Ophthalmology and Visual Science 2001 42 8 1679 1684 2-s2.0-0034942895 (Pubitemid 32652337)
104. Bauer J., Kilic E., Vaarwater J., Bastian B. C., Garbe C., De Klein A., Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. British Journal of Cancer 2009 101 5 813 815 10.1038/sj.bjc.6605226 2-s2.0-70249134535
105. Brantley M. A. Jr., Harbour J. W., Deregulation of the Rb and p53 pathways in uveal melanoma. American Journal of Pathology 2000 157 6 1795 1801 2-s2.0-0033637120
106. Coupland S. E., Anastassiou G., Stang A., The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. Journal of Pathology 2000 191 2 120 126 10.1002/(SICI)1096-9896(200006)191:2<120::AID- PATH591>3.0.CO;2-P 2-s2.0-0034129488 (Pubitemid 30394887)
107. Coupland S. E., Bechrakis N., Schüler A., Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. British Journal of Ophthalmology 1998 82 8 961 970 2-s2.0-0031679192 (Pubitemid 28408159)
108. Ghana J. S., Wilson G. D., Cree I. A., c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. British Journal of Ophthalmology 1999 83 1 110 114 2-s2.0-0033008658 (Pubitemid 29106343)
109. Jay V., Yi Q., Hunter W. S., Zielenska M., Expression of bcl-2 in uveal malignant melanoma. Archives of Pathology and Laboratory Medicine 1996 120 5 497 498 2-s2.0-0029934066 (Pubitemid 26157179)
110. Singh A. D., Wang M. X., Donoso L. A., Shields C. L., De Potter P., Shields J. A., Genetic aspects of uveal melanoma: a brief review. Seminars in Oncology 1996 23 6 768 772 2-s2.0-0030472220 (Pubitemid 26424706)
111. Ehlers J. P., Worley L., Onken M. D., Harbour J. W., Integrative genomic analysis of aneuploidy in uveal melanoma. Clinical Cancer Research 2008 14 1 115 122 10.1158/1078-0432.CCR-07-1825 2-s2.0-40749137815 (Pubitemid 351377985)
112. Abdel-Rahman M. H., Yang Y., Zhou X.-P., Craig E. L., Davidorf F. H., Eng C., High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. Journal of Clinical Oncology 2006 24 2 288 295 10.1200/JCO.2005.02.2418 2-s2.0-33644822256 (Pubitemid 46622057)
113. Wan P. T. C., Garnett M. J., Roe S. M., Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004 116 6 855 867 10.1016/S0092-8674(04)00215-6 2-s2.0-12144289677 (Pubitemid 38410730)
114. Randazzo P. A., Andrade J., Miura K., The Arf GTPase-activating protein ASAP1 regulates the actin cytoskeleton. Proceedings of the National Academy of Sciences of the United States of America 2000 97 8 4011 4016 10.1073/pnas.070552297 2-s2.0-0034635994 (Pubitemid 30226078)
115. Liu Y., Loijens J. C., Martin K. H., Karginov A. V., Parsons J. T., The association of ASAP1, an ADP ribosylation factor-GTPase activating protein, with focal adhesion kinase contributes to the process of focal adhesion assembly. Molecular Biology of the Cell 2002 13 6 2147 2156 10.1091/mbc.E02-01-0018 2-s2.0-0035985220 (Pubitemid 34651498)
116. McGill G. G., Horstmann M., Widlund H. R., Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002 109 6 707 718 10.1016/S0092-8674(02)00762-6 2-s2.0-18444418797 (Pubitemid 34722267)
117. Wellbrock C., Karasarides M., Marais R., The RAF proteins take centre stage. Nature Reviews Molecular Cell Biology 2004 5 11 875 885 10.1038/nrm1498 2-s2.0-8444238236 (Pubitemid 39486539)
118. Platz A., Egyhazi S., Ringborg U., Hansson J., Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Molecular Oncology 2008 1 4 395 405 10.1016/j.molonc. 2007.12.003 2-s2.0-40849094167
119. Chuang J. C., Jones P. A., Epigenetics and microRNAs. Pediatric Research 2007 61 5, part 2 24R 29R 10.1203/pdr.0b013e3180457684 2-s2.0-34247540446 (Pubitemid 46653064)
120. Merbs S. L., Sidransky D., Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma. Investigative Ophthalmology and Visual Science 1999 40 3 779 783 2-s2.0-0032978249 (Pubitemid 29109459)
121. van der Veiden P. A., Metzelaar-Blok J. A. W., Bergman W., Promoter hypermethylation: a common cause of reduced p16INK4a expression in uveal melanoma. Cancer Research 2001 61 13 5303 5306 2-s2.0-0035392955 (Pubitemid 32681568)
122. Maat W., van der Velden P. A., Out-Luiting C., Epigenetic inactivation of RASSF1a in uveal melanoma. Investigative Ophthalmology and Visual Science 2007 48 2 486 490 10.1167/iovs.06-0781 2-s2.0-33847757494 (Pubitemid 351260675)
123. Moulin A. P., Clément G., Bosman F. T., Zografos L., Benhattar J., Methylation of CpG island promoters in uveal melanoma. British Journal of Ophthalmology 2008 92 2 281 285 10.1136/bjo.2007.127035 2-s2.0-38949117297 (Pubitemid 351224112)
124. Worley L. A., Long M. D., Onken M. D., Harbour J. W., Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Research 2008 18 3 184 190 10.1097/CMR. 0b013e3282feeac6 2-s2.0-43649087713 (Pubitemid 351684663)
125. Radhakrishnan A., Badhrinarayanan N., Biswas J., Krishnakumar S., Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma. Molecular Vision 2009 15 2146 2154 2-s2.0-73449111297
126. Bemis L. T., Chen R., Amato C. M., MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Research 2008 68 5 1362 1368 10.1158/0008-5472.CAN-07-2912 2-s2.0-40449094344 (Pubitemid 351346843)
127. Segura M. F., Hanniford D., Menendez S., Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proceedings of the National Academy of Sciences of the United States of America 2009 106 6 1814 1819 10.1073/pnas.0808263106 2-s2.0-60549112361
128. Felicetti F., Errico M. C., Segnalini P., Mattia G., Carè A., MicroRNA-221 and -222 pathway controls melanoma progression. Expert Review of Anticancer Therapy 2008 8 11 1759 1765 10.1586/14737140.8.11.1759 2-s2.0-60849117008
129. Johnson S. M., Grosshans H., Shingara J., RAS is regulated by the let-7 microRNA family. Cell 2005 120 5 635 647 10.1016/j.cell.2005.01.014 2-s2.0-20044395613 (Pubitemid 40343076)
130. Singh A. D., Topham A., Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 2003 110 5 962 965 10.1016/S0161-6420(03)00077- 0 2-s2.0-0037880737 (Pubitemid 36560497)
131. Shields C. L., Ganguly A., Materin M. A., Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases: the Deborah Iverson, MD, Lectureship. Archives of Ophthalmology 2007 125 8 1017 1024 10.1001/archopht.125.8.1017 2-s2.0-34547914770 (Pubitemid 47258031)
132. Midena E., Bonaldi L., Parrozzani R., Tebaldi E., Boccassini B., Vujosevic S., In vivo detection of monosomy 3 in eyes with medium-sized uveal melanoma using transscleral fine needle aspiration biopsy. European Journal of Ophthalmology 2006 16 3 422 425 2-s2.0-33745923188 (Pubitemid 44049285)
133. Young T. A., Rao N. P., Glasgow B. J., Moral J. N., Straatsma B. R., Fluorescent in situ hybridization of monosomy 3 via 30-gauge fine-needles aspiration biopsy of choroidal melanoma in vivo. Ophthalmology 2007 114 1 142 146 10.1016/j.ophtha.2006.06.040 2-s2.0-33845786576 (Pubitemid 46014278)
134. Shields C. L., Materin M. A., Teixeira L., Mashayekhi A., Ganguly A., Shields J. A., Small choroidal melanoma with chromosome 3 monosomy on fine-needle aspiration biopsy. Ophthalmology 2007 114 10 1919 1924 10.1016/j.ophtha.2007.04.054 2-s2.0-34748867334 (Pubitemid 47483932)